Cambridge, UK, 3rd January 2023, Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery.
Dr. Jhoti co-founded Astex in 1999 to pioneer the development of fragment-based drug discovery (FBDD), a ground-breaking new approach now widely used in the pharmaceutical industry, and which the company has used to help discover two new marketed cancer…
Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services
Former CEO, Dr David Hughes, appointed to Scientific Advisory Board
Cambridge, UK, 19 December 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative…
Click here to view the December 2022 edition of The Meeting Place
Asahi Kasei Pharma offers collaborative research opportunities with research funding and our scientists’ contribution through research activities.
We will be accepting research proposals for 2023 during the following period.5:00AM, Jan 5, 2023 GMT to 8:00AM, Feb 28, 2023 GMT
A short video overviewing the program is now available!
More information here
”ASAHI KASEI PHARMA OPEN INNOVATION” is an open innovation platform started in 2018 to recruit candidates for research collaborations related to drug discovery.
In 2020, we have established a new corporate philosophy that expresses "Our…
Cambridge, UK, 14 December 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ distinctive technologies in high-throughput drug discovery, PhoreMost’s next-generation phenotypic screening platform, SITESEEKER®, and ThinkCyte’s AI-driven cell…
AMSBIO announce a new range of different isolation products for fast, scalable, and reproducible purification of Extracellular Vesicles (EV), including exosomes, as well as addressing EV heterogeneity and high throughput solutions for biomarker discovery.
Traditionally ultracentrifugation has been the favored method for EV isolation or separation. Though it is still widely used, ultracentrifugation not only tends to alter the vesicle shape and functionality but is time-consuming and requires expensive equipment. The EV isolation product range from AMSBIO sets a new gold standard for…
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed a project manager to lead the preclinical development of its in-licensed triple negative breast cancer treatment, CLX001.
Zai Ahmad has over 20 years’ experience in oncology, neuroscience, and drug development and joins the ValiRx team from Oxford Biomedica, where she was principal scientist and product research and development team lead. Zai has previously held roles at Covance, AstraZeneca, The Institute of Cancer Research, the University of Leeds, the University of Oxford,…
Read the latest People Pathways newsletter for your monthly round up of employee engagement activities.
PRESS RELEASE
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
Oxford, UK – 14th December 2022 – PrecisionLife Limited (“PrecisionLife”), a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases today announced that it has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. (“Ono”), an R&D-orientated pharmaceutical company. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated…
Scott Maidment appointed as Head of HTS to lead the new service
Expanded facilities gives Company total of 20,160 sq. ft at Granta Park, Cambridge, UK
Cambridge, UK, 30 November 2022: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facilities. Scott Maidment has been appointed as Head of HTS to lead the new service.
The Company has signed a nine-year lease for an additional 8,…